Holen Sie sich die Stockscreener-App
6.16
2.53%
-0.16
Schlusskurs vom Vortag:
$6.32
Offen:
$5.99
24-Stunden-Volumen:
1.71M
Relative Volume:
0.51
Marktkapitalisierung:
$552.24M
Einnahmen:
$20.65M
Nettoeinkommen (Verlust:
$-192.65M
KGV:
-2.3784
EPS:
-2.59
Netto-Cashflow:
$-134.39M
1W Leistung:
-0.56%
1M Leistung:
+48.08%
6M Leistung:
+7.88%
1J Leistung:
+10.00%
1-Tages-Spanne:
$5.88
$6.2553
1-Wochen-Bereich:
$5.78
$6.6675
52-Wochen-Spanne:
$2.8647
$9.305
Verve Therapeutics Inc Stock (VERV) Company Profile
Firmenname
Verve Therapeutics Inc
Sektor
Branche
Telefon
(978) 501-3026
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie VERV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
6.16 | 552.24M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-10-06 | Eingeleitet | Credit Suisse | Neutral |
| 2022-08-25 | Hochstufung | Stifel | Hold → Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-07-12 | Eingeleitet | Guggenheim | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-12 | Eingeleitet | Jefferies | Buy |
| 2021-07-12 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten
Verve Therapeutics’ SWOT analysis: gene editing stock shows promise amid challenges By Investing.com - Investing.com South Africa
Verve Therapeutics’ SWOT analysis: gene editing stock shows promise amid challenges - Investing.com UK
What Makes Verve Therapeutics (VERV) a New Buy Stock - Yahoo Finance
Brokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) PT at $25.75 - Defense World
Verve Therapeutics reports voting results from annual meeting By Investing.com - Investing.com South Africa
Verve Therapeutics Holds Annual Stockholders Meeting - TipRanks
Verve Therapeutics reports voting results from annual meeting - Investing.com
Long Term Trading Analysis for (VERV) - news.stocktradersdaily.com
Transcript : Verve Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 11 - marketscreener.com
Verve Therapeutics wins FDA fast track status for cholesterol treatment - MSN
Lost Money on Verve Therapeutics, Inc.(VERV)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Transcript : Verve Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 09 - marketscreener.com
Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average - Yahoo Finance
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - Yahoo Finance
BNP Paribas Financial Markets Purchases Shares of 8,876 Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by ProShare Advisors LLC - Defense World
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Verve Therapeutics Grants Equity Awards to New Employees as Part of Inducement Stock Incentive Plan - Nasdaq
Latest Employee Stock Grants: Verve Therapeutics Issues 87,000 Shares Worth of Equity Awards - Stock Titan
Bank of America Corp DE Reduces Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Ameriprise Financial Inc. - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Deutsche Bank AG - Defense World
Nuveen Asset Management LLC Sells 355,953 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
37,984 Shares in Verve Therapeutics, Inc. (NASDAQ:VERV) Acquired by D. E. Shaw & Co. Inc. - Defense World
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVERV - ACCESS Newswire
Canaccord Genuity Reaffirms Their Buy Rating on Verve Therapeutics (VERV) - The Globe and Mail
Verve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely - simplywall.st
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Verve Therapeutics (NASDAQ:VERV) Upgraded at Wall Street Zen - Defense World
Northern Trust Corp Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Transcript : Verve Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03 - marketscreener.com
Analysts Offer Predictions for VERV FY2026 Earnings - Defense World
3 Top Genomics Stocks to Add to Your Portfolio in 2025 - Yahoo Finance
Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks - simplywall.st
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts - simplywall.st
Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher - Yahoo Finance
Cantor Fitzgerald Issues Positive Outlook for VERV Earnings - Defense World
Price T Rowe Associates Inc. MD Lowers Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), Nkarta (NKTX) and Kamada (KMDA) - The Globe and Mail
Dimensional Fund Advisors LP Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics: Q1 Earnings Snapshot - CT Insider
Verve Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire
Verve Therapeutics (VERV) Beats Q1 EPS Estimates, Reports Signif - GuruFocus
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Verve Therapeutics (VERV) Exceeds Revenue Estimates and Advances - GuruFocus
Verve Therapeutics, Inc. SEC 10-Q Report - TradingView
Finanzdaten der Verve Therapeutics Inc-Aktie (VERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):